OakChart

Revolution Medicines Inc

RVMDHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 3:59 PM ET

180.70-12.36 (-6.40%)
2026-11-12 00:28 CET
Market cap
41,757.33 USD m
Revenue, TTM
197.56 USD m
Net income, TTM
-1,870.54 USD m
Free cash flow, TTM
-1,440.82 USD m
EPS diluted, TTM
-9.10
P/E
-
Compare

Price

RVMD against its 20, 50 and 200-day averages
2050200beatmiss
100.00150.00200.004.8M9.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RVMDclose 180.7020-day 189.0650-day 195.89200-day 159.11180.7052w high

19.4% under the 52-week high of 224.31 on 27 Aug 2026. 52-week low 62.29 on 11 Nov 2025. Last 15 sessions, 19.4% high to low

Volume 1.57× normal · the line is the 50-bar volume average

Profile

RVMD
52-week range, 73% of the way up
62.29224.31

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

IndexRUI
Employees883
IPOFeb 13, 2020
Beta1.43
ATR, 14d10.63
Rel volume1.57
Short float6.71%
Insider own9.93%
Inst own94.34%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap39.08B
Enterprise Value36.64B
Income-1.87B
Sales197.56M
Book/sh11.11
Cash/sh16.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees883
IPOFeb 13, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S197.83
P/B16.27
P/C10.70
P/FCF-
EV/EBITDA-
EV/Sales185.48
Quick Ratio8.34
Current Ratio8.36
Debt/Eq0.50
LT Debt/Eq0.50
Option/ShortYes / Yes

Earnings

EPS (ttm)-9.10
EPS next Y-2.95
EPS next Q-1.21
EPS this Y-43.04%
EPS next Y65.34%
EPS next 5Y-
EPS past 3/5Y-24.48% -29.13%
Sales past 3/5Y- -
EPS Y/Y TTM-75.59%
Sales Y/Y TTM-100.00%
EPS Q/Q-17.53%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.18.98% 672.54%

Ownership

Insider Own9.93%
Insider Trans-2.45%
Inst Own94.34%
Inst Trans5.77%
ROA-57.07%
ROE-93.56%
ROIC-51.91%
Gross Margin90.31%
Oper. Margin-852.98%
Profit Margin-946.82%
SMA20-4.42%
SMA50-7.76%
SMA20013.57%
Trades-

Technical

Shs Outstand216.25M
Shs Float194.80M
Short Float6.71%
Short Ratio6.30
Short Interest13.08M
52W High224.31 -19.44%
52W Low62.29 190.09%
Volatility8.34% 5.35%
ATR (14)10.63
RSI (14)43.67
Beta1.43
Rel Volume1.57
Avg Volume2.07M
Volume3,259,324

Performance

Perf Week-9.51%
Perf Month-4.11%
Perf Quarter-10.54%
Perf Half Y20.51%
Perf YTD126.87%
Perf Year181.99%
Perf 3Y816.79%
Perf 5Y463.98%
Perf 10Y-
Recom1.08
Target Price275.80
Prev Close193.06
Price180.70
Change %-6.40%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Sep 24, 2026ResumedGGoldmanBuy$267+47.8%
Sep 10, 2026InitiatedMMorgan StanleyOverweight$255+41.1%
May 22, 2026InitiatedBBernsteinMkt Perform$151-16.4%
May 18, 2026ResumedTTruistBuy$179-0.9%
Mar 16, 2026ResumedJJefferiesBuy
Feb 27, 2026ResumedUUBSBuy$145-19.8%
Nov 18, 2025InitiatedWWolfe ResearchOutperform$75-58.5%
Nov 03, 2025InitiatedRRBC Capital MktsOutperform$77-57.4%
Oct 21, 2025InitiatedMMizuhoOutperform$90-50.2%

Peers

Mkt cap
TickerCompanyMkt cap
ERASErasca Inc5.88B
BBOTBridgeBio Oncology Therapeutics Inc205.24M
ONCBeOne Medicines Ltd ADR44.22B
VSTMVerastem Inc1.15B
EXELExelixis Inc17.25B
AMGNAMGEN Inc253.21B
BMYBristol-Myers Squibb Co128.59B
INCYIncyte Corp24.92B
SMMTSummit Therapeutics Inc13.27B
GMABGenmab ADR33.13B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Mancini AnthonySee RemarksOct 26 '26Option Exercise33.622,31077,66242,075Oct 28 06:00 PM
Mancini AnthonySee RemarksOct 26 '26Sale186.992,310431,94739,765Oct 28 06:00 PM
Sandler Alan B.Chief Development OfficerSep 29 '26Option Exercise58.846,000353,04058,868Oct 01 06:00 PM
Sandler Alan B.Chief Development OfficerSep 29 '26Sale202.146,3091,275,29452,559Oct 01 06:00 PM
Cislini JeffSVP & General CounselSep 25 '26Sale207.32765158,60051,776Sep 29 06:00 PM
ALAN SANDLEROfficerSep 29 '26Proposed Sale201.746,3091,272,778Sep 29 04:24 PM
Mancini AnthonySee RemarksSep 25 '26Option Exercise33.623,121104,92842,886Sep 28 06:00 PM
Mancini AnthonySee RemarksSep 25 '26Sale200.543,121625,88539,765Sep 28 06:00 PM
Mancini AnthonySee RemarksSep 24 '26Sale200.00587117,40039,765Sep 28 06:00 PM
ANTHONY MANCINIOfficerSep 25 '26Proposed Sale199.869,3631,871,289Sep 25 04:17 PM
ANDERSON ELIZABETH MDirectorSep 22 '26Option Exercise1.125,0705,67814,476Sep 24 06:00 PM
ANDERSON ELIZABETH MDirectorSep 22 '26Sale193.0410,1431,958,0164,333Sep 24 06:00 PM
ANTHONY MANCINIOfficerSep 24 '26Proposed Sale190.74587111,964Sep 24 04:42 PM
Mancini AnthonySee RemarksSep 18 '26Sale196.941,764347,40240,352Sep 22 06:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.09B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWFiShares Russell 1000 Growth ETFAUM: 116.57B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-1.900-2.345-1.899197.6225.5822
2026Q22026-08-05-3.060-2.043-3.0550.001.7719
2026Q12026-05-06-2.290-1.836-2.2910.002.4319
2025Q42026-02-25-1.860-1.581-1.8550.003.6820
2025Q32025-11-05-1.610-1.421-1.6130.001.6920
2025Q22025-08-06-1.310-1.138-1.3140.0027.5311
2025Q12025-05-07-1.130-1.091-1.1340.000.0010
2024Q42025-02-26-1.120-0.986-1.1200.000.3815
2024Q32024-11-06-0.940-0.893-0.9370.000.3515
2024Q22024-08-07-0.810-0.775-0.8070.000.8115
2024Q12024-05-08-0.700-0.746-0.7040.001.3711
2023Q42024-02-26-1.140-0.853-1.1440.740.6710
2023Q32023-11-06-0.990-1.011-0.9930.000.758
2023Q22023-08-08-0.920-0.823-0.9203.821.568
2023Q12023-05-08-0.720-0.803-0.7187.013.399
2022Q42023-02-27-0.630-0.822-0.63415.337.8010

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-22.330--1.04950.01-
2020FY-2.010-1.826-1.65742.9850.97
2021FY-2.570-2.503-2.57029.3928.78
2022FY-3.080-3.292-3.08535.3827.86
2023FY-3.860-3.478-3.85711.5812.65
2024FY-3.580-3.473-3.5780.000.30
2025FY-5.950-5.647-5.9500.003.48
2026FY--8.511--568.29
2027FY--2.950--2,000
2028FY-0.665--3,362
2029FY-7.473--5,516
2030FY-16.353--8,662

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1121190388.6644.62635
2026Q4S2026-11-0621200388.6644.62635
2026Q4S2026-11-0521200378.1744.62635
2026Q4S2026-11-0421133183.9544.62330.98
2026Q4S2026-10-2621133183.9644.62330.98
2026Q4S2026-10-2121133183.9644.62330.98
2026Q4S2026-10-2021133183.6644.62330.98
2026Q4S2026-10-1621123174.610.00330.98
2026Q4S2026-10-1421123173.410.00330.98
2026Q4S2026-10-0920123178.450.00330.98
2026Q4S2026-10-0720132175.680.00330.98
2026Q4S2026-10-0520132175.260.00330.98
2026Q4S2026-10-0220132174.770.00330.98
2026Q4S2026-09-2819132167.550.00330.98

Estimate history

EPS, annual-0.591-0.827-1.049-1.657-2.57-3.085-3.857-3.578-5.95-9.0973
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.937-1.12-1.134-1.314-1.613-1.855-2.291-3.055-1.896
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual020.16550.04142.98329.3935.3811.5800197.56
Period201720182019202020212022202320242025TTM
Sales, quarterly00000000197.559
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual59.00259.00259.00166.674.14390.412164.675185.897197.001216.252
Period201720182019202020212022202320242025MRQ
Shares, quarterly167.748185.897186.258186.901189.711197.001200.179214.243216.252
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue197.560.000.0011.5835.3829.3942.9850.0420.16
Cost of Goods Sold Incl. D&A19.1516.5611.829.319.667.33--1.76
Gross Profit178.41-16.56-11.822.2725.7222.06--18.40
Selling, General and Administrative Excl. Other1,863.541,165.81677.70489.46284.00210.07147.13100.2258.33
Research and Development1,438.71978.68584.60417.03248.03182.80128.5791.1651.08
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-1,685.13-1,182.37-689.52-487.19-258.28-188.01-110.70-53.52-39.93
Interest Expense81.7224.230.000.000.000.010.070.110.12
Unusual Expense220.1515.36-4.32-0.120.000.000.000.002.52
Net Income Before Taxes-1,872.89-1,131.30-600.85-439.89-249.12-187.09-108.53-52.04-41.79
Income Taxes-2.350.00-0.75-3.52-0.420.00-0.37-4.370.00
Consolidated Net Income-1,870.54-1,131.30-600.09-436.37-248.71-187.09-108.16-47.66-41.79
Net Income From Continuing Operations-1,870.54-1,131.30-600.09-436.37-248.71-187.09-108.16-47.66-41.79
Net Income-1,870.54-1,131.30-600.09-436.37-248.71-187.09-110.38-61.90-48.82
EPS (Recurring)-7.99-5.89-3.60-3.86-3.08-2.57-1.66-1.05-0.80
EPS (Basic, Before Extraordinaries)-9.10-5.95-3.58-3.86-3.08-2.57-1.66-1.05-0.83
EPS (Diluted)-9.10-5.95-3.58-3.86-3.08-2.57-1.66-1.05-0.83
EBITDA-1,666.01-1,165.81-677.70-477.88-248.62-180.68-104.15-50.18-38.16
Non-Operating Income (Expense)114.1190.6684.3647.189.150.932.241.590.78
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense237.09118.3962.5748.8024.6420.726.492.310.85
Price To Sales Ratio223.32--280.2454.2862.3561.34--
Gross Margin90.31--19.6172.7175.05--91.25
Operating Margin-852.98---4,207.12-730.01-639.70-257.54-106.96-198.01
Net Margin-946.82---3,768.28-702.95-636.58-256.79-123.70-242.10
Shares Outstanding216.25197.00185.90164.6790.4174.1466.6059.0059.00
Market Capitalization41,757.3341,757.337,975.993,142.322,115.001,854.702,627.992,715.61-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue197.560.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A5.414.504.544.704.343.803.723.39
Gross Profit192.15-4.50-4.54-4.70-4.34-3.80-3.72-3.39
Selling, General and Administrative Excl. Other565.30500.63440.69356.92310.93260.91237.04212.92
Research and Development412.00392.47341.62292.61260.18222.11203.79186.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-373.15-505.13-445.22-361.63-315.27-264.71-240.76-216.31
Interest Expense33.8023.7812.2011.9411.430.000.000.00
Unusual Expense40.70151.0315.7912.630.594.58-2.440.22
Net Income Before Taxes-409.81-644.37-453.82-364.89-305.21-247.79-213.42-195.32
Income Taxes-2.350.000.000.000.000.000.00-0.75
Consolidated Net Income-407.46-644.37-453.82-364.89-305.21-247.79-213.42-194.57
Net Income From Continuing Operations-407.46-644.37-453.82-364.89-305.21-247.79-213.42-194.57
Net Income-407.46-644.37-453.82-364.89-305.21-247.79-213.42-194.57
EPS (Recurring)-1.76-2.55-2.24-1.81-1.61-1.30-1.14-1.12
EPS (Basic, Before Extraordinaries)-1.90-3.06-2.29-1.86-1.61-1.31-1.13-1.12
EPS (Diluted)-1.90-3.06-2.29-1.86-1.61-1.31-1.13-1.12
EBITDA-367.77-500.63-440.69-356.92-310.93-260.91-237.04-212.92
Non-Operating Income (Expense)37.8435.5719.3921.3022.0821.5024.9121.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense49.1067.0087.3033.7030.7828.8325.085.81
Price To Sales Ratio223.32-------
Gross Margin97.26-------
Operating Margin-188.88-------
Net Margin-206.25-------
Shares Outstanding216.25214.24200.18197.00189.71186.90186.26185.90
Market Capitalization41,757.3339,814.9819,272.3215,397.948,729.776,852.806,573.887,975.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2,025.682,289.301,852.95644.94577.05440.74122.7669.599.08
Short Term Receivables0.000.001.254.675.936.398.747.300.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets49.3638.3325.0710.576.796.992.498.540.36
Total Current Assets2,075.042,327.631,879.28660.18589.77454.12133.9885.439.44
Net Property, Plant & Equipment165.28141.82100.0173.7471.2436.347.156.875.25
Total Investments and Advances4.863.703.031.741.741.080.210.210.00
Intangible Assets70.4171.2872.3573.4274.4875.5576.6277.690.00
Deferred Tax Assets53.8845.1026.8926.2627.9719.4310.842.910.00
Other Assets38.9313.877.032.860.760.302.570.380.38
Total Assets2,408.392,603.402,088.59838.19765.96586.83231.36173.5015.08
Short Term Debt Incl. Current Port. of LT Debt16.4712.877.376.776.213.690.170.150.00
Accounts Payable64.6254.4361.7921.3114.0612.6111.405.243.35
Other Current Liabilities209.3496.6174.6933.9140.0830.8831.4825.174.25
Total Current Liabilities290.42163.91143.8561.9860.3547.1843.0530.557.60
Long Term Debt410.68122.9780.5857.4360.4228.990.000.000.00
Provision for Risks Charges0.003.196.510.000.000.000.000.000.00
Deferred Tax Liabilities56.2447.4530.0033.2835.4126.8818.6515.110.00
Other Liabilities19.750.671.460.307.219.1117.1231.182.95
Total Liabilities777.09338.19262.40153.00163.39112.1678.8376.8410.55
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00305.11205.0872.25
Common Equity1,631.302,265.201,826.19685.19602.57474.68-152.57-108.42-67.72
Total Shareholders Equity1,631.302,265.201,826.19685.19602.57474.68152.5396.664.53
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,631.302,265.201,826.19685.19602.57474.68152.5396.664.53
Total Liabilities & Stockholders Equity2,408.392,603.402,088.59838.19765.96586.83231.36173.5015.08
Book Value Per Share8.2812.1911.097.588.137.13-2.59-1.84-1.15
Tangible Book Value Per Share7.9211.8010.656.777.125.99-3.88-3.15-1.15
Full-Time Employees88353437824618812595--
Price to Book Ratio17.384.683.753.073.105.555.37--
Return on Assets-45.15-25.58-29.82-31.01-27.66-26.44-23.55-44.32-
Return on Equity-58.07-29.33-34.75-38.63-34.74-34.49-38.25-82.60-
Return on Invested Capital-55.40-25.13-22.89-33.49-28.22-21.47-31.25-43.23-686.98
Quick Ratio7.1414.2013.0610.659.779.633.112.801.24
Current Ratio7.1414.2013.0610.659.779.633.112.801.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1,870.54-1,131.30-600.09-436.37-248.71-187.09-108.16-47.66-41.79
Depreciation19.1416.5611.829.319.667.336.543.341.76
Other Funds (Non Cash)534.94130.1830.4339.7328.1423.869.853.533.18
Funds from Operations-1,316.45-984.56-558.60-391.23-211.33-155.90-92.14-45.16-36.85
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-114.9286.821.1740.66-13.078.72-7.93-4.4638.06
Cash from Operating Activities-1,431.37-897.74-557.44-350.57-224.40-147.18-100.06-49.621.21
Capital Expenditures-9.45-15.99-10.31-7.73-10.82-6.53-2.93-2.59-1.50
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.16
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.006.200.00
Purchase or Sale of Investments-1,321.63134.05-544.09-334.87-13.30-135.59-231.30-105.580.00
Purchase of Investments-3,085.32-1,794.85-2,136.62-1,058.92-612.77-671.34-544.13-172.270.00
Sale Or Maturity of Investments1,763.691,928.901,592.54724.05599.47535.75312.8366.690.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1,331.08118.06-554.39-342.60-24.12-142.12-234.23-101.97-1.34
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2,439.63377.09959.13392.39301.39294.18422.7898.6660.85
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.04-0.13
Sale of Common Pref Stock2,439.63377.09959.13392.39301.39294.18422.7898.7060.98
Proceedsfrom Stock Options2,416.42355.95954.10389.07299.53292.30421.9498.7060.98
Issuance or Reduction of Debt, Net976.28244.220.000.000.000.000.000.000.00
Change in Long Term Debt976.28244.220.000.000.000.000.000.000.00
Issuance of Long Term Debt976.28244.220.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-244.020.220.28836.810.040.000.000.000.00
Other Financing Activities Uses0.000.000.00-4.030.000.000.000.000.00
Cash from Financing Activities3,171.89621.52959.411,229.20301.43294.18422.7898.6660.85
Net Change in Cash409.44-158.16-152.42536.0352.914.8888.48-52.9360.72
Free Cash Flow-1,440.82-913.73-567.74-358.30-235.22-153.71-103.00-52.20-0.29
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.00-0.76-3.91-0.420.00-0.38-4.370.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments3,651.393,937.971,908.082,025.681,931.512,137.17
Short Term Receivables230.720.000.000.000.000.00
Inventories11.020.000.000.000.000.00
Other Current Assets83.5790.3759.8349.3645.9839.27
Total Current Assets3,976.704,028.341,967.912,075.041,977.492,176.44
Net Property, Plant & Equipment160.02162.45161.37165.28167.38147.05
Total Investments and Advances15.834.864.864.864.863.92
Intangible Assets70.0870.4170.4170.4170.4870.74
Deferred Tax Assets---53.88--
Other Assets80.8857.2149.1938.9331.7231.42
Total Assets4,303.514,323.272,253.742,408.392,251.922,429.57
Short Term Debt Incl. Current Port. of LT Debt9.3816.7516.6116.4716.3313.09
Accounts Payable100.6688.4280.5464.6274.8556.76
Other Current Liabilities365.63248.89192.45209.34154.45114.69
Total Current Liabilities475.67354.06289.60290.42245.62184.53
Long Term Debt1,202.031,173.72420.66410.68142.13119.70
Provision for Risks Charges0.000.000.000.005.925.33
Deferred Tax Liabilities-2.352.3556.242.352.35
Other Liabilities224.31186.9041.2119.75258.99252.28
Total Liabilities1,902.011,717.03753.82777.09655.02564.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2,401.502,606.241,499.921,631.301,596.901,865.37
Total Shareholders Equity2,401.502,606.241,499.921,631.301,596.901,865.37
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2,401.502,606.241,499.921,631.301,596.901,865.37
Total Liabilities & Stockholders Equity4,303.514,323.272,253.742,408.392,251.922,429.57
Book Value Per Share11.1112.167.498.288.429.98
Tangible Book Value Per Share10.7811.847.147.928.059.60
Full-Time Employees---883-700
Price to Book Ratio17.3824.9911.749.464.683.30
Return on Assets-57.07-52.37-59.39-45.15-47.87-38.32
Return on Equity-93.56-79.09-76.67-58.07-60.76-46.61
Return on Invested Capital-11.31-17.05-23.63-17.87-17.55-12.48
Quick Ratio8.3411.386.807.148.0511.79
Current Ratio8.3611.386.807.148.0511.79

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-407.46-644.37-453.82-364.89-305.21-247.79
Depreciation5.414.504.544.704.343.80
Other Funds (Non Cash)131.70237.48112.0653.7137.1126.53
Funds from Operations-270.35-402.39-337.22-306.48-263.75-217.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-145.3015.07-16.9532.2556.44-4.30
Cash from Operating Activities-415.65-387.32-354.17-274.24-207.31-221.76
Capital Expenditures-3.70-2.29-1.54-1.93-3.35-7.45
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments83.79-1,656.38174.1576.8128.2041.73
Purchase of Investments-540.75-2,038.36-209.73-296.49-459.04-529.29
Sale Or Maturity of Investments624.54381.98383.89373.29487.24571.02
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities80.10-1,658.67172.6274.8824.8534.28
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock147.001,688.42238.74365.474.156.58
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock147.001,688.42238.74365.474.156.58
Proceedsfrom Stock Options145.211,688.18238.69344.344.146.58
Issuance or Reduction of Debt, Net-0.00732.070.00244.220.000.00
Change in Long Term Debt-0.00732.070.00244.220.000.00
Issuance of Long Term Debt-0.00732.070.00244.220.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-244.02-5.74250.00
Other Financing Activities Uses0.000.000.000.000.020.00
Cash from Financing Activities147.002,420.49238.74365.66-1.59256.58
Net Change in Cash-188.56374.5057.19166.30-184.0569.10
Free Cash Flow-419.35-389.61-355.70-276.16-210.66-229.21

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.71%13.1M194.8M1.92M
2026-10-156.70%12.9M193.0M1.95M
2026-09-306.18%11.9M193.0M1.94M
2026-09-155.01%9.7M193.0M2.21M
2026-08-315.04%9.7M192.8M2.46M
2026-08-145.04%9.7M192.8M2.57M
2026-07-316.01%11.5M191.7M2.70M
2026-07-157.37%14.0M190.1M3.09M
2026-06-306.78%12.9M190.1M3.49M
2026-06-156.46%12.3M190.1M3.07M
2026-05-296.09%11.6M190.4M2.91M
2026-05-155.83%11.1M190.1M2.91M
2026-04-306.91%12.8M185.2M2.86M
2026-04-157.38%13.4M181.4M2.86M
2026-03-318.95%15.4M172.3M3.31M
2026-03-138.39%14.5M172.3M3.40M
2026-02-278.19%14.1M172.3M3.40M
2026-02-138.13%13.7M168.0M3.35M
2026-01-307.91%13.1M165.3M3.45M
2026-01-158.60%14.2M165.3M3.14M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12060.0062.900.002.1720.000.000.966-0.2010.021
call12554.5058.100.002.0020.000.000.963-0.1980.023
call13049.6053.1063.901.8582.000.000.959-0.1940.025
call13545.1048.2069.001.6971.000.000.955-0.1900.027
call14040.2043.100.001.5580.000.000.950-0.1860.029
call14535.2038.3043.781.4192.000.000.945-0.1800.031
call15030.2033.4033.001.28126.0010.000.938-0.1740.034
call15525.6028.6041.511.1422.000.000.908-0.2220.047
call16020.7023.8038.001.0263.000.000.893-0.2100.052
call16516.3019.4026.900.9152.000.000.799-0.3520.079
call17012.3015.3014.650.83339.008.000.748-0.3400.090
call1758.6011.8011.150.79416.0011.000.648-0.3940.104
call1806.109.307.670.82836.008.000.540-0.4700.112
call1854.107.105.200.79527.0014.000.449-0.4930.111
call1902.605.503.840.85241816.000.375-0.5050.107
call1952.003.502.200.7571064.000.280-0.4090.095
call2001.252.901.400.81179734.000.232-0.3980.086
call2100.502.100.650.9151,32715.000.164-0.3630.070
call2200.301.300.440.95682219.000.107-0.2820.052
call2300.151.050.201.0524732.000.083-0.2570.043
call2400.002.300.451.1881790.000.075-0.2700.040
call2500.001.300.301.04584.002.000.028-0.1080.018
call2600.050.200.931.08124.001.000.019-0.0800.013
call2700.002.150.201.1746.000.000.018-0.0820.012
call2800.001.101.251.37811.000.000.063-0.2770.039
call2900.002.150.001.3471.000.000.016-0.0850.011
call3000.002.150.201.4279.000.000.015-0.0870.011
call3100.002.150.151.50410.000.000.014-0.0880.010
put1200.002.200.051.5532.000.00-0.034-0.1880.021
put1250.002.200.321.4222.000.00-0.037-0.1840.023
put1300.002.250.501.2953.000.00-0.041-0.1800.025
put1350.001.700.281.17125.000.00-0.045-0.1750.027
put1400.052.100.121.05041.000.00-0.050-0.1700.029
put1450.002.400.440.93316.000.00-0.055-0.1640.031
put1500.250.650.350.81687014.00-0.062-0.1580.034
put1550.051.500.850.78528.000.00-0.092-0.2050.047
put1600.501.000.800.6621107.00-0.107-0.1920.052
put1650.203.001.270.7472350.00-0.201-0.3340.079
put1701.352.452.000.5971,23629.00-0.252-0.3210.090
put1752.154.203.800.57248217.00-0.352-0.3750.104
put1804.106.706.000.63845812.00-0.460-0.4500.112
put1857.2010.509.200.73014713.00-0.551-0.4720.111
put19010.6013.9012.200.7471962.00-0.625-0.4840.107
put19514.4017.309.210.72523.000.00-0.720-0.3870.095
put20018.8021.4017.500.73955.004.00-0.768-0.3760.086
put21028.0031.0019.900.8878.000.00-0.836-0.3400.070
put22037.5040.5027.770.97822.000.00-0.893-0.2580.052
put23047.3050.3033.771.0921.000.00-0.917-0.2320.043
put24057.4060.400.001.2560.000.00-0.925-0.2430.040
put25067.3070.0057.001.2860.000.00-0.972-0.0800.018
put26077.3080.400.001.5140.000.00-0.981-0.0510.013
put27087.2090.2075.001.5790.000.00-0.982-0.0520.012
put28097.30100.885.001.6600.000.00-0.983-0.0530.012
put290107.3110.688.201.8230.000.00-0.984-0.0530.011
put300117.3120.40.001.8950.000.00-0.985-0.0530.011
put310127.3130.60.002.0790.000.00-0.986-0.0530.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-30SCHEDULE 13GSEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-138-KCurrent report2026-10-08SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-29144Filing for proposed sale of securities under Rule 144.SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-24144Filing for proposed sale of securities under Rule 144.SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-18144Filing for proposed sale of securities under Rule 144.SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000431.95K1
2026-090036.73M16
2026-080041.28M4
2026-070000
2026-060024.01M10
2026-0500480.61K1
2026-040018.42M2
2026-030010.36M11
2026-020000
2026-01008.63M3
2025-12002.42M5
2025-110011.45M8

Institutional holders

Manager% owned
FMR LLC7.18%
Jupiter Topco LLC6.74%
BlackRock, Inc.6.44%
FARALLON CAPITAL MANAGEMENT, L.L.C.6.37%
BAKER BROS. ADVISORS LP5.38%
Darwin Global Management, Ltd.5.00%
VANGUARD CAPITAL MANAGEMENT LLC4.28%
VANGUARD PORTFOLIO MANAGEMENT LLC3.90%
Nextech Invest Ltd.3.58%
Paradigm Biocapital Advisors LP2.99%

Funds

Fund% owned
NYLIM MacKay Convertible Fund11.21%
CALAMOS STRATEGIC TOTAL RETURN FUND6.81%
NYLIM VP MacKay Convertible Portfolio5.64%
Calamos Growth & Income Fund5.24%
iShares Convertible Bond ETF4.82%
Columbia Convertible Securities Fund3.73%
State Street(R) SPDR(R) Bloomberg Convertible Securities ETF3.48%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
Calamos Market Neutral Income Fund2.61%
Lord Abbett Convertible Fund2.61%

OakChart. RVMD. Cached 15 minutes.